Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.43 AUD | -3.37% | +11.69% | +24.64% |
03:03am | Canaccord Starts Immutep at Buy, Price Target is AU$1.00 | MT |
24/04 | Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck | MT |
Sales 2024 * | 3.19M 2.08M 174M | Sales 2025 * | 17.82M 11.62M 971M | Capitalization | 529M 345M 28.82B |
---|---|---|---|---|---|
Net income 2024 * | -44M -28.69M -2.4B | Net income 2025 * | -42M -27.39M -2.29B | EV / Sales 2024 * | 142 x |
Net cash position 2024 * | 75.11M 48.98M 4.09B | Net cash position 2025 * | 61.67M 40.22M 3.36B | EV / Sales 2025 * | 26.2 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
1 day | -3.37% | ||
1 week | +11.69% | ||
Current month | +13.16% | ||
1 month | +10.26% | ||
3 months | +22.86% | ||
6 months | +34.38% | ||
Current year | +24.64% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 01/11/01 |
David Fang
DFI | Director of Finance/CFO | - | 01/18/01 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 08/13/08 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 01/11/01 |
Anne Anderson
BRD | Director/Board Member | - | 14/02 |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 0.43 | -3.37% | 3 428 321 |
29/24/29 | 0.445 | +5.95% | 2,651,345 |
26/24/26 | 0.42 | -6.67% | 4,968,700 |
24/24/24 | 0.45 | +16.88% | 13,371,270 |
23/24/23 | 0.385 | +8.45% | 1,433,061 |
Delayed Quote Australian S.E., April 30, 2024 at 11:40 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.64% | 347M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- IMM Stock